AVTR

Avantor

AVTR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,077

Bullish sentiment (50-day avg)95%

Price to earnings ratio14.9

Market capitalization10.3B

Earnings per share-0.85

Dividend yield (TTM)—

Revenue (annual)6.6B

Net income (annual)-530.2M

Social

What share of all stock conversation is about AVTR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jul 29

Avantor, Inc. ($AVTR) stock is up 71% since a purchase by former President Trump, who filed a May 22nd purchase of $AVTR stock.
Avantor reported Q2 2026 results with net sales of $1,692.3 million and adjusted EPS of $0.21, alongside operating cash flow of $178.2 million and free cash flow of $142.8 million.
Avantor's 'Revival' turnaround plan is showing tangible results, with the VWR Distribution & Services segment reversing a string of declines to post +1.7% organic growth, pulling total organic net sales up 0.4%.

Generated by AI

Sentiment

Of the messages about AVTR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +5	66.91% +7.29
Bearish	—	—	0% -5	33.09% -7.29

Aug 2

Avantor ($AVTR) has been upgraded to overweight by Piper Sandler, with a price target raised to $41.
Multiple analysts have raised Avantor's price target, including Morgan Stanley to $44, Truist Securities to $45, and Citigroup to $45.
Avantor's stock has seen significant gains, increasing by 70% in 10 months, and is breaking out above $38.04 with a target of $39.43.

Generated by AI

Topics

Of the messages about AVTR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	0%	62.16%	13.33%
Announcements	—	0%	5.41%	56.32%
Analysts	—	50%	18.92%	8.34%
Controversies	—	0%	0%	17.38%
Macro	—	50%	13.51%	1.74%
Earnings	—	0%	0%	2.9%

Analysts· Feb 7

Morgan Stanley and Raymond James have both lowered their price target for Avantor ($AVTR) to $43, with Morgan Stanley maintaining an Overweight rating and Raymond James maintaining an Outperform rating.
Barclays has raised its price target for Avantor ($AVTR) to $44, maintaining an Overweight rating, while Robert W. Baird has lowered its target to $43.
Analysts at Morgan Stanley, Raymond James, Barclays, and Robert W. Baird have recently updated their price targets for Avantor ($AVTR), with some maintaining their previous ratings and others lowering or raising their targets.

Announcements· Apr 25

Avantor, Inc. (AVTR) reported Q1 2025 results with adjusted EPS of $0.23, beating estimates, and revenue of $1.58B, missing estimates.
Michael Stubblefield, Avantor's CEO, intends to step down and will be retained by the board until February 2026 to provide input to the new CEO.
Avantor plans to raise its cost transformation target to $400M by 2027 to boost growth, amid reduced Education & Government demand in its Lab Solutions segment.

Generated by AI

Community

Of the messages about AVTR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	60%	72.48%	46.68%
Newcomers	—	40%	27.52%	53.32%

Regulars· Oct 29

Avantor's Q3 2025 earnings missed expectations, with adjusted EPS at $0.22, a 15.4% decline from the same period last year, and revenue falling 5.3% YoY.
The company reported a net loss of $712 million, with GAAP EPS impacted by a $785 million goodwill impairment.
Avantor's board has approved a $500 million buyback, and the company's operating cash flow and free cash flow came in at $207.4 million and $171.7 million, respectively.

Newcomers· Jul 29

Trump's recent purchase of Avantor stock ($AVTR) has sparked interest, with the stock up 71% since the purchase.
Despite being a pharma company, Avantor gets relatively little love in the market, despite its better valuation, exposure to biosimilars, and excellent new team.
Avantor's Q2 2026 results showed a 4.2% revenue increase and GAAP EPS of $0.06, but net income crashed 41% YoY due to a tax rate spike.

Generated by AI

Avantor has appointed Todd Garner as Executive Vice President and Chief Financial Officer, effective 21 September 2026, placing him in charge of its global finance organization, including planning, accounting, treasury, tax, investor relations and internal audit. Garner’s three decades of finance and public company leadership, including prior CFO roles and extensive investor relations experience, could meaningfully influence Avantor’s capital allocation and communication with the...

7d agoYahoo Finance

Avantor Appoints Todd Garner as New Chief Financial Officer

Detailed price information for Avantor Inc (AVTR-N) from The Globe and Mail including charting and trades.

8d agoThe Globe and Mail

Are Medical Stocks Lagging Avantor (AVTR) This Year?

Here is how Avantor, Inc. (AVTR) and BrightSpring Health Services, Inc. (BTSG) have performed compared to their sector so far this year.

8d agoYahoo Finance

Avantor Names Todd Garner as CFO

Avantor (AVTR) has named Todd Garner as chief financial officer, effective immediately, the company

9d agoYahoo Finance

Avantor names Todd Garner as chief financial officer

9d agoInvesting.com

Avantor appoints new Chief Financial Officer – Company Announcement

9d agoFinancial Times

Also Discussed

Investors talking about AVTR also mention

#	Name	Attention
1	ASGN Inc.ASGN	0%0
2	Thermo Fisher Scientific Inc.TMO	0%0
3	PKI - PerkinElmer, Inc.	——
4	Danaher Corp.DHR	0.02%+0.02
5	Ambev S.A. ADRABEV	0%0
6	BrightSpring Health Services, Inc.BTSG	0%new
7	CTLT - Catalent, Inc.	——
8	Mettler-Toledo International Inc.MTD	0%new
9	Clarivate PlcCLVT	0%0
10	Compass Therapeutics, Inc.CMPX	0%new

Avantor, Inc.

Healthcare
Medical Instruments & Supplies

Avantor, Inc. is a global life science tools and advanced technology company that supplies mission-critical products and services to customers in biopharma, healthcare, education and government, and applied materials industries. Its portfolio includes laboratory chemicals, reagents, consumables, equipment, instrumentation, single-use bioprocessing components, and specialty services that support research, development, production, and quality control. The company also provides customized materials and procurement solutions for highly regulated environments, helping laboratories and production teams maintain consistent workflows across the scientific supply chain. Avantor serves customers across the Americas, Europe, Asia, the Middle East, and Africa, with operations centered in Radnor, Pennsylvania.

Website

Location

Radnor Corporate Center

Radnor, PA, 19087

United States

Social

What share of all stock conversation is about AVTR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jul 29

Avantor, Inc. ($AVTR) stock is up 71% since a purchase by former President Trump, who filed a May 22nd purchase of $AVTR stock.
Avantor reported Q2 2026 results with net sales of $1,692.3 million and adjusted EPS of $0.21, alongside operating cash flow of $178.2 million and free cash flow of $142.8 million.
Avantor's 'Revival' turnaround plan is showing tangible results, with the VWR Distribution & Services segment reversing a string of declines to post +1.7% organic growth, pulling total organic net sales up 0.4%.

Generated by AI

Sentiment

Of the messages about AVTR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +5	66.91% +7.29
Bearish	—	—	0% -5	33.09% -7.29

Aug 2

Avantor ($AVTR) has been upgraded to overweight by Piper Sandler, with a price target raised to $41.
Multiple analysts have raised Avantor's price target, including Morgan Stanley to $44, Truist Securities to $45, and Citigroup to $45.
Avantor's stock has seen significant gains, increasing by 70% in 10 months, and is breaking out above $38.04 with a target of $39.43.

Generated by AI

Topics

Of the messages about AVTR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	0%	62.16%	13.33%
Announcements	—	0%	5.41%	56.32%
Analysts	—	50%	18.92%	8.34%
Controversies	—	0%	0%	17.38%
Macro	—	50%	13.51%	1.74%
Earnings	—	0%	0%	2.9%

Analysts· Feb 7

Morgan Stanley and Raymond James have both lowered their price target for Avantor ($AVTR) to $43, with Morgan Stanley maintaining an Overweight rating and Raymond James maintaining an Outperform rating.
Barclays has raised its price target for Avantor ($AVTR) to $44, maintaining an Overweight rating, while Robert W. Baird has lowered its target to $43.
Analysts at Morgan Stanley, Raymond James, Barclays, and Robert W. Baird have recently updated their price targets for Avantor ($AVTR), with some maintaining their previous ratings and others lowering or raising their targets.

Announcements· Apr 25

Avantor, Inc. (AVTR) reported Q1 2025 results with adjusted EPS of $0.23, beating estimates, and revenue of $1.58B, missing estimates.
Michael Stubblefield, Avantor's CEO, intends to step down and will be retained by the board until February 2026 to provide input to the new CEO.
Avantor plans to raise its cost transformation target to $400M by 2027 to boost growth, amid reduced Education & Government demand in its Lab Solutions segment.

Generated by AI

Community

Of the messages about AVTR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	60%	72.48%	46.68%
Newcomers	—	40%	27.52%	53.32%

Regulars· Oct 29

Avantor's Q3 2025 earnings missed expectations, with adjusted EPS at $0.22, a 15.4% decline from the same period last year, and revenue falling 5.3% YoY.
The company reported a net loss of $712 million, with GAAP EPS impacted by a $785 million goodwill impairment.
Avantor's board has approved a $500 million buyback, and the company's operating cash flow and free cash flow came in at $207.4 million and $171.7 million, respectively.

Newcomers· Jul 29

Trump's recent purchase of Avantor stock ($AVTR) has sparked interest, with the stock up 71% since the purchase.
Despite being a pharma company, Avantor gets relatively little love in the market, despite its better valuation, exposure to biosimilars, and excellent new team.
Avantor's Q2 2026 results showed a 4.2% revenue increase and GAAP EPS of $0.06, but net income crashed 41% YoY due to a tax rate spike.

Generated by AI

Avantor

Social

Jul 29

Sentiment

Aug 2

Topics

Analysts· Feb 7

Announcements· Apr 25

Community

Regulars· Oct 29

Newcomers· Jul 29

News

How Avantor’s New CFO Appointment At Avantor (AVTR) Has Changed Its Investment Story

Avantor Appoints Todd Garner as New Chief Financial Officer

Are Medical Stocks Lagging Avantor (AVTR) This Year?

Avantor Names Todd Garner as CFO

Avantor names Todd Garner as chief financial officer

Avantor appoints new Chief Financial Officer – Company Announcement

Also Discussed

Avantor, Inc.

Company Information

Location

News

How Avantor’s New CFO Appointment At Avantor (AVTR) Has Changed Its Investment Story

Avantor Appoints Todd Garner as New Chief Financial Officer

Are Medical Stocks Lagging Avantor (AVTR) This Year?

Avantor Names Todd Garner as CFO

Avantor names Todd Garner as chief financial officer

Avantor appoints new Chief Financial Officer – Company Announcement

Also Discussed

Social

Jul 29

Sentiment

Aug 2

Topics

Analysts· Feb 7

Announcements· Apr 25

Community

Regulars· Oct 29

Newcomers· Jul 29